Trial Profile
A Randomized Phase 2 Trial of Peginterferon Lambda-1a (Lambda) for the Treatment of Hospitalized Patients Infected With SARS-CoV-2 With Non-critical Illness
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon lambda-1a (Primary) ; Anti-infectives; Hydroxychloroquine
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 24 Feb 2021 Status changed from not yet recruiting to withdrawn prior to enrolment. Due to the number of competing trials at their site, the study team has closed enrollment and withdrawn this trial.
- 11 Jun 2020 Planned initiation date changed from 1 May 2020 to 1 Sep 2020.
- 18 May 2020 New trial record